Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

The U.S. Food and Drug Administration has approved Elanco Animal Health's oral drug to protect dogs against six parasitic ...

Two thirds of people around the world struggle to access mental health support but can we economically afford to continue down this path?

In this episode of The Big Question, Nedim Pipic, Senior Vice President and Global Head of Mental Health at Boehringer Ingelheim sat ... or around one third of China’s GDP.

The increasing demand for asthma treatment is largely driven by the rising number of asthma cases. Factors such as increased smoking and air pollution are impairing lung function and contributing to ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...

A woman, 25, with type 1 diabetes started producing insulin (blue) after a stem cell transplant and is now considered to have reversed her conditionCredit: Lennart Nilsson, Boehringer Ingelheim ...